175 related articles for article (PubMed ID: 19643988)
1. Mer receptor tyrosine kinase is a novel therapeutic target in pediatric B-cell acute lymphoblastic leukemia.
Linger RM; DeRyckere D; Brandão L; Sawczyn KK; Jacobsen KM; Liang X; Keating AK; Graham DK
Blood; 2009 Sep; 114(13):2678-87. PubMed ID: 19643988
[TBL] [Abstract][Full Text] [Related]
2. Mer receptor tyrosine kinase is a therapeutic target in pre-B-cell acute lymphoblastic leukemia.
Linger RM; Lee-Sherick AB; DeRyckere D; Cohen RA; Jacobsen KM; McGranahan A; Brandão LN; Winges A; Sawczyn KK; Liang X; Keating AK; Tan AC; Earp HS; Graham DK
Blood; 2013 Aug; 122(9):1599-609. PubMed ID: 23861246
[TBL] [Abstract][Full Text] [Related]
3. Role of c-Myb in the survival of pre B-cell acute lymphoblastic leukemia and leukemogenesis.
Sarvaiya PJ; Schwartz JR; Hernandez CP; Rodriguez PC; Vedeckis WV
Am J Hematol; 2012 Oct; 87(10):969-76. PubMed ID: 22764095
[TBL] [Abstract][Full Text] [Related]
4. Mer tyrosine kinase promotes the survival of t(1;19)-positive acute lymphoblastic leukemia (ALL) in the central nervous system (CNS).
Krause S; Pfeiffer C; Strube S; Alsadeq A; Fedders H; Vokuhl C; Loges S; Waizenegger J; Ben-Batalla I; Cario G; Möricke A; Stanulla M; Schrappe M; Schewe DM
Blood; 2015 Jan; 125(5):820-30. PubMed ID: 25428221
[TBL] [Abstract][Full Text] [Related]
5. UNC569, a novel small-molecule mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo.
Christoph S; Deryckere D; Schlegel J; Frazer JK; Batchelor LA; Trakhimets AY; Sather S; Hunter DM; Cummings CT; Liu J; Yang C; Kireev D; Simpson C; Norris-Drouin J; Hull-Ryde EA; Janzen WP; Johnson GL; Wang X; Frye SV; Earp HS; Graham DK
Mol Cancer Ther; 2013 Nov; 12(11):2367-77. PubMed ID: 23997116
[TBL] [Abstract][Full Text] [Related]
6. GAS6/Mer axis regulates the homing and survival of the E2A/PBX1-positive B-cell precursor acute lymphoblastic leukemia in the bone marrow niche.
Shiozawa Y; Pedersen EA; Taichman RS
Exp Hematol; 2010 Feb; 38(2):132-40. PubMed ID: 19922767
[TBL] [Abstract][Full Text] [Related]
7. Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia.
Lee-Sherick AB; Eisenman KM; Sather S; McGranahan A; Armistead PM; McGary CS; Hunsucker SA; Schlegel J; Martinson H; Cannon C; Keating AK; Earp HS; Liang X; DeRyckere D; Graham DK
Oncogene; 2013 Nov; 32(46):5359-68. PubMed ID: 23474756
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity.
Keating AK; Kim GK; Jones AE; Donson AM; Ware K; Mulcahy JM; Salzberg DB; Foreman NK; Liang X; Thorburn A; Graham DK
Mol Cancer Ther; 2010 May; 9(5):1298-307. PubMed ID: 20423999
[TBL] [Abstract][Full Text] [Related]
9. Lymphoblastic leukemia/lymphoma in mice overexpressing the Mer (MerTK) receptor tyrosine kinase.
Keating AK; Salzberg DB; Sather S; Liang X; Nickoloff S; Anwar A; Deryckere D; Hill K; Joung D; Sawczyn KK; Park J; Curran-Everett D; McGavran L; Meltesen L; Gore L; Johnson GL; Graham DK
Oncogene; 2006 Oct; 25(45):6092-100. PubMed ID: 16652142
[TBL] [Abstract][Full Text] [Related]
10. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.
O'Farrell AM; Abrams TJ; Yuen HA; Ngai TJ; Louie SG; Yee KW; Wong LM; Hong W; Lee LB; Town A; Smolich BD; Manning WC; Murray LJ; Heinrich MC; Cherrington JM
Blood; 2003 May; 101(9):3597-605. PubMed ID: 12531805
[TBL] [Abstract][Full Text] [Related]
11. Antileukemia Effects of Notch-Mediated Inhibition of Oncogenic PLK1 in B-Cell Acute Lymphoblastic Leukemia.
Kannan S; Aitken MJL; Herbrich SM; Golfman LS; Hall MG; Mak DH; Burks JK; Song G; Konopleva M; Mullighan CG; Chandra J; Zweidler-McKay PA
Mol Cancer Ther; 2019 Sep; 18(9):1615-1627. PubMed ID: 31227645
[TBL] [Abstract][Full Text] [Related]
12. Bcl-2 Is a Therapeutic Target for Hypodiploid B-Lineage Acute Lymphoblastic Leukemia.
Diaz-Flores E; Comeaux EQ; Kim KL; Melnik E; Beckman K; Davis KL; Wu K; Akutagawa J; Bridges O; Marino R; Wohlfeil M; Braun BS; Mullighan CG; Loh ML
Cancer Res; 2019 May; 79(9):2339-2351. PubMed ID: 30862722
[TBL] [Abstract][Full Text] [Related]
13. Ectopic expression of the proto-oncogene Mer in pediatric T-cell acute lymphoblastic leukemia.
Graham DK; Salzberg DB; Kurtzberg J; Sather S; Matsushima GK; Keating AK; Liang X; Lovell MA; Williams SA; Dawson TL; Schell MJ; Anwar AA; Snodgrass HR; Earp HS
Clin Cancer Res; 2006 May; 12(9):2662-9. PubMed ID: 16675557
[TBL] [Abstract][Full Text] [Related]
14. UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor.
Zhang W; DeRyckere D; Hunter D; Liu J; Stashko MA; Minson KA; Cummings CT; Lee M; Glaros TG; Newton DL; Sather S; Zhang D; Kireev D; Janzen WP; Earp HS; Graham DK; Frye SV; Wang X
J Med Chem; 2014 Aug; 57(16):7031-41. PubMed ID: 25068800
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapy with MXD3 siRNA, anti-CD22 antibody and nanoparticles for precursor B-cell acute lymphoblastic leukaemia.
Satake N; Duong C; Chen C; Barisone GA; Diaz E; Tuscano J; Rocke DM; Nolta J; Nitin N
Br J Haematol; 2014 Nov; 167(4):487-99. PubMed ID: 25196579
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy.
Sengupta TK; Leclerc GM; Hsieh-Kinser TT; Leclerc GJ; Singh I; Barredo JC
Mol Cancer; 2007 Jul; 6():46. PubMed ID: 17623090
[TBL] [Abstract][Full Text] [Related]
17. Targeting of the deubiquitinase USP9X attenuates B-cell acute lymphoblastic leukemia cell survival and overcomes glucocorticoid resistance.
Zhou M; Wang T; Lai H; Zhao X; Yu Q; Zhou J; Yang Y
Biochem Biophys Res Commun; 2015 Apr; 459(2):333-339. PubMed ID: 25735983
[TBL] [Abstract][Full Text] [Related]
18. FLT3 tyrosine kinase as a target in acute leukemias.
Griffin JD
Hematol J; 2004; 5 Suppl 3():S188-90. PubMed ID: 15190306
[No Abstract] [Full Text] [Related]
19. Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia.
Shi PJ; Xu LH; Lin KY; Weng WJ; Fang JP
J Hematol Oncol; 2016 Feb; 9():12. PubMed ID: 26892465
[TBL] [Abstract][Full Text] [Related]
20. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia.
Peirs S; Matthijssens F; Goossens S; Van de Walle I; Ruggero K; de Bock CE; Degryse S; Canté-Barrett K; Briot D; Clappier E; Lammens T; De Moerloose B; Benoit Y; Poppe B; Meijerink JP; Cools J; Soulier J; Rabbitts TH; Taghon T; Speleman F; Van Vlierberghe P
Blood; 2014 Dec; 124(25):3738-47. PubMed ID: 25301704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
